IP Library Granted Patent US 9,045,474
Granted Patent B2
US 9,045,474 · App. 13/813,923 · Granted Jun 2, 2015

Compounds and compositions for mitigating tissue damage and lethality

Inventors: Robert H. Schiestl (Encino, CA); Yelena O. Rivina (Los Angeles, CA); Michael E. Jung (Los Angeles, CA); Robert Damoiseaux (Beverly Hills, CA)
Assignee: The Regents of the University of California
C07D471/04A61K31/00A61K31/381A61K31/437A61K31/4709G01N33/5088G01N2800/40A61K45/06A61N5/10C07D333/38C07D409/12C12Q1/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,045,474
App. No.
13/813,923
Granted
Jun 2, 2015
Kind
B2
Abstract

Embodiments of the present invention provide compounds and compositions thereof, which are effective for mitigating tissue damage or lethality induced by an agent, and methods of making and using the same.

Claims (13)

1. A method of mitigating tissue damage, genetic instability, or lethality induced by radiation or a chemical carcinogen in a cell, the method comprising contacting the cell with a compound having a structure of Formula IA

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein the compound is administered in a pharmaceutical composition that further comprises a pharmaceutically acceptable excipient.

3. The method of claim 1 , wherein said tissue damage, genetic instability, or lethality is induced by radiation and the radiation is selected from radiation emitted by a radioactive element, alpha radiation, beta radiation, gamma radiation, neutron radiation, x radiation, and ultraviolet radiation.

4. The method according to claim 1 , wherein the tissue damage, genetic instability, or lethality is induced by exposure to radiation from a nuclear reactor.

5. The method according to claim 2 , wherein the composition further comprises a second agent.

6. The method according to claim 5 , wherein the second agent is a therapeutic agent.

7. The method according to claim 6 , wherein the second agent is selected from amifostine, free radical scavengers, growth factors, immune modulators, anti-apoptotic agents and/or capture agents.

8. The method according to claim 2 , wherein 0.05% to 10 wt % of the composition is an active ingredient.

9. The method according to claim 1 , wherein the method reduces cell death or genetic instability by a percentage of 5% or higher.

10. The method according to claim 1 , wherein the method reduces cell death or genetic instability by a percentage of 10% or higher.

11. The method according to claim 1 , wherein the method reduces cell death or genetic instability by a percentage of 25% or higher.

12. The method according to claim 1 , wherein the method reduces cell death or genetic instability by a percentage of 50% or higher.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 7, 2013
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029941/0303 →
Continuity (2)
Provisional Application 61370386 · Aug 3, 2010
Related Publication 20130231518A1 · Sep 5, 2013